Mediwound Ltd MDWD.OQ MDWD.O is expected to show a rise in quarterly revenue when it reports results on March 19 for the period ending December 31 2024
The Yavne Israel-based company is expected to report a 7.7% increase in revenue to $5.748 million from $5.34 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Mediwound Ltd is for a loss of 61 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mediwound Ltd is $30.00, above its last closing price of $18.54.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.45 | -0.44 | -0.98 | Missed | -121.1 |
Jun. 30 2024 | -0.43 | -0.42 | -0.68 | Missed | -61.9 |
Mar. 31 2024 | -0.41 | -0.41 | -1.05 | Missed | -158.2 |
Dec. 31 2023 | -0.33 | -0.23 | -0.19 | Beat | 16.5 |
Sep. 30 2023 | -0.45 | -0.44 | -0.24 | Beat | 45.8 |
Jun. 30 2023 | -0.42 | -0.40 | 0.10 | Beat | 124.8 |
Mar. 31 2023 | -0.29 | -0.30 | -0.44 | Missed | -44.3 |
Dec. 31 2022 | -0.38 | -0.59 | -1.18 | Missed | -100 |
This summary was machine generated March 17 at 12:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。